Verona Pharma Announces March 2025 Investor Conference Participation
Verona Pharma (Nasdaq: VRNA) has announced its participation in two major healthcare investor conferences in March 2025. The company will present corporate overviews at the TD Cowen 45th Annual Health Care Conference in Boston on March 3 at 11:10 a.m. ET, and at the Leerink Partners 2025 Global Healthcare Conference in Miami on March 10 at 8:40 a.m. ET.
The company specializes in developing treatments for chronic respiratory diseases, with their flagship product Ohtuvayre™ (ensifentrine), the first inhaled COPD maintenance therapy combining bronchodilator and anti-inflammatory properties. Webcasts of both presentations will be available on the company's website.
Verona Pharma (Nasdaq: VRNA) ha annunciato la sua partecipazione a due importanti conferenze per investitori nel settore sanitario a marzo 2025. L'azienda presenterà panoramiche aziendali alla TD Cowen 45ª Conferenza Annuale sulla Salute a Boston il 3 marzo alle 11:10 a.m. ET, e alla Leerink Partners 2025 Conferenza Globale sulla Salute a Miami il 10 marzo alle 8:40 a.m. ET.
L'azienda si specializza nello sviluppo di trattamenti per malattie respiratorie croniche, con il suo prodotto di punta Ohtuvayre™ (ensifentrina), la prima terapia di mantenimento per la BPCO inalata che combina proprietà broncodilatatrici e antinfiammatorie. Le trasmissioni in diretta di entrambe le presentazioni saranno disponibili sul sito web dell'azienda.
Verona Pharma (Nasdaq: VRNA) ha anunciado su participación en dos importantes conferencias de inversores en el sector salud en marzo de 2025. La compañía presentará una visión general corporativa en la 45ª Conferencia Anual de Salud de TD Cowen en Boston el 3 de marzo a las 11:10 a.m. ET, y en la Conferencia Global de Salud 2025 de Leerink Partners en Miami el 10 de marzo a las 8:40 a.m. ET.
La compañía se especializa en el desarrollo de tratamientos para enfermedades respiratorias crónicas, siendo su producto insignia Ohtuvayre™ (ensifentrina), la primera terapia de mantenimiento para EPOC inhalada que combina propiedades broncodilatadoras y antiinflamatorias. Las transmisiones de ambas presentaciones estarán disponibles en el sitio web de la empresa.
베로나 파마 (Nasdaq: VRNA)는 2025년 3월에 열리는 두 개의 주요 헬스케어 투자자 회의에 참가한다고 발표했습니다. 회사는 3월 3일 오전 11시 10분 ET에 보스턴에서 열리는 TD Cowen 제45회 연례 헬스케어 회의와 3월 10일 오전 8시 40분 ET에 마이애미에서 열리는 Leerink Partners 2025 글로벌 헬스케어 회의에서 기업 개요를 발표할 예정입니다.
회사는 만성 호흡기 질환 치료제 개발을 전문으로 하며, 대표 제품인 Ohtuvayre™ (엔시펜트린)은 기관지 확장제와 항염증제의 특성을 결합한 최초의 흡입형 COPD 유지 요법입니다. 두 발표의 웹캐스트는 회사 웹사이트에서 제공될 예정입니다.
Verona Pharma (Nasdaq: VRNA) a annoncé sa participation à deux grandes conférences pour investisseurs dans le secteur de la santé en mars 2025. L'entreprise présentera des aperçus de son activité lors de la 45e Conférence Annuelle de Santé de TD Cowen à Boston le 3 mars à 11h10 ET, et lors de la Conférence Mondiale de Santé 2025 de Leerink Partners à Miami le 10 mars à 8h40 ET.
L'entreprise se spécialise dans le développement de traitements pour les maladies respiratoires chroniques, avec son produit phare Ohtuvayre™ (ensifentrine), la première thérapie de maintien pour la BPCO inhalée combinant des propriétés bronchodilatatrices et anti-inflammatoires. Les webcasts des deux présentations seront disponibles sur le site web de l'entreprise.
Verona Pharma (Nasdaq: VRNA) hat seine Teilnahme an zwei bedeutenden Investorenkonferenzen im Gesundheitswesen im März 2025 angekündigt. Das Unternehmen wird Unternehmensübersichten auf der 45. jährlichen Gesundheitskonferenz von TD Cowen in Boston am 3. März um 11:10 Uhr ET und auf der Leerink Partners 2025 Global Healthcare Conference in Miami am 10. März um 8:40 Uhr ET präsentieren.
Das Unternehmen ist auf die Entwicklung von Behandlungen für chronische Atemwegserkrankungen spezialisiert und hat mit Ohtuvayre™ (Ensifentrin) das erste inhalative Erhaltungstherapeutikum für COPD, das Bronchodilatator- und entzündungshemmende Eigenschaften kombiniert. Webcasts beider Präsentationen werden auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
LONDON and RALEIGH, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in March 2025:
TD Cowen 45th Annual Health Care Conference
Date: Monday, March 3, 2025
Time: 11:10 a.m. ET / 4:10 p.m. GMT
Location: Boston, MA
Leerink Partners 2025 Global Healthcare Conference
Date: Monday, March 10, 2025
Time: 8:40 a.m. ET / 1:40 p.m. GMT
Location: Miami, FL
A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com.
For further information please contact:
| Verona Pharma plc | Tel: +1-844-341-9901 |
| Victoria Stewart, Senior Director of Investor Relations and Communications | IR@veronapharma.com |
| Argot Partners US Investor Enquiries | Tel: +1-212-600-1902 verona@argotpartners.com |
| Ten Bridge Communications International / US Media Enquiries | Tel: +1-781-316-4424 tbcverona@tenbridgecommunications.com |
| Wendy Ryan |
About Verona Pharma
Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre™ (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.
FAQ
When and where will Verona Pharma (VRNA) present at the TD Cowen Healthcare Conference in 2025?
When is Verona Pharma's (VRNA) presentation at the Leerink Partners Conference in 2025?
What is Verona Pharma's (VRNA) main product Ohtuvayre used for?
How can investors access Verona Pharma's (VRNA) March 2025 conference presentations?
